Wingrove Theresa, SVP of Regulatory Affairs at ImmunoGen (IMGN), has demonstrated a clear selling bias in recent transactions, according to SEC Form 4 filings. Since late 2023, her activity has been concentrated exclusively on IMGN, with $5.91 million in total sales outweighing $971,693 in purchases. The most significant transactions occurred in early 2024, including a $5.56 million sale on January 16 and a $352,391 disposition on February 5. These sales were accompanied by smaller acquisitions through market transactions, such as $284,487 and $153,352 worth of shares on January 16, and a $9,846 award acquisition on December 29, 2023.
The pattern shows a consistent reduction in Theresa’s IMGN holdings, with no recent purchases offsetting the sales. The transactions appear to be methodical, with the largest sale executed shortly after the new year and another in early February. While some of the activity involves derivative transactions (coded "M" and "A"), the outright sales (coded "S") dominate in both frequency and volume. Given that all trades involve a single company, the data suggests a focused divestment strategy rather than portfolio rebalancing across multiple holdings. The absence of any recent buys further reinforces the directional trend toward reducing exposure to IMGN.
AI-assisted summary